Glycogen Storage Disorders (GSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competi
November 5, 2024 ⚊ 1 Min read ⚊ Views 12 ⚊ NEWSThis reports provides a data-driven overview of the current and future competitive landscape in Glycogen Storage Disorders therapeutics.
In 2024, more than 2,000 diagnosed incident cases of GSD are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast.
Most of the marketed drugs for GSD are enzyme replacement therapies.
The Phase III pipeline consists of two drugs, with seven drugs in Phase II; there are no drugs in the pre-registrational stage.
Tags: glycogen storage disorders competitive analysis